Now the UK Government’s pursuit of an SPS agreement with the European Union threatens to leave British businesses paying for a regulatory failure they did not create.

The UK Government has committed to a new direction for food and agricultural regulation through its Sanitary and Phytosanitary (SPS) agreement with the EU.

For the CBD industry, this is not simply about smoother trade. It raises a far more uncomfortable question: how can the Government change the regulatory framework before its own authorities have finished the job?

Six years. No final authorisations.

The Food Standards Agency (FSA) required CBD businesses to invest in scientific dossiers, toxicological studies, product testing and extensive compliance procedures.

Industry complied, often at considerable expense.

Yet more than six years later, the authorisation process remains unfinished.

Marika Graham-Woods, CEO and Chairman of the Cannabis Trades Association (CTA), recently highlighted that 10,374 validated CBD entries remained on the FSA Public List, while only six high-purity CBD dossiers had passed or received positive safety assessments. Just three had progressed towards ministerial consideration, with none receiving final authorisation.

These figures expose an extraordinary imbalance between the obligations imposed on industry and the outcomes delivered by regulators.

The SPS agreement compounds the failure

The agreement introduces dynamic alignment with relevant EU legislation, including novel foods and food supplements.

Under the intended arrangements, EU authorisations would apply in Great Britain, while existing domestic authorisations would cease to apply unless exceptions were secured.

For CBD businesses, this raises fundamental questions about the status of existing applications, recognition of scientific evidence, continued market access and the potential cost of entering another regulatory process.

The UK would also be required to follow relevant future EU rules without the voting rights of an EU Member State.

Regulatory control is being traded away before domestic regulatory obligations have been fulfilled.

The CTA has consistently advocated mutual recognition and scientifically justified equivalence rather than automatic dynamic alignment.

Removing trade barriers should not mean sacrificing regulatory accountability.

Who pays for regulatory failure?

Businesses have invested substantial sums because the Government required them to follow a particular authorisation pathway.

Those investments cannot simply be written off because political priorities have changed.

For smaller companies, further delays, duplicated assessments or uncertain market access could threaten commercial viability.

Meanwhile, the Government promotes the SPS agreement as an economic opportunity without adequately explaining what happens to businesses caught between the two regulatory systems.

The FSA did not negotiate the agreement. Ministers did.

But the Agency remains accountable for the administration of the unfinished CBD authorisation process, just as Government remains responsible for the consequences of changing it.

Neither can reasonably use the other’s decisions to avoid scrutiny.

Political expediency is not accountability

Marika Graham-Woods recently challenged the tendency for political developments to become convenient explanations for unresolved regulatory responsibilities.

Political change is legitimate. Avoiding accountability is not.

That distinction matters.

The CTA is not arguing against international cooperation or rigorous scientific assessment. It is challenging a system in which businesses are expected to comply indefinitely while those responsible for regulatory decisions face little apparent consequence for prolonged delays.

The Government must explain what protections have been secured for existing CBD applicants, whether their scientific investment will be recognised and how continuity of lawful market access will be maintained.

It must also account for the wider implications for industrial hemp, ensuring agricultural alignment does not undermine legitimate cultivation and processing.

The Government must answer for its decisions

The CBD industry followed the rules. It invested in compliance and waited for the promised regulatory decisions.

Now the Government has chosen a different direction before completing the process it established.

The SPS agreement cannot erase six years of responsibility or transfer the cost of unfinished regulation onto compliant businesses.

As Marika Graham-Woods concluded:

Political expediency must never become an excuse for regulatory failure.